Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

References

• Santus P, Radovanovic D, Paggiaro P, et al. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur J Intern Med. 2015;26(6):379–384.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
   PubMed Web of Science ®Google Scholar
• Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):7–16.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease,GOLD. Revision 2016. [ cited 2016 Jun 2].
   Google Scholar
• Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17(1):35–39.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Resp Med. 2006;100(11):1925–1932.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196.
   PubMed Web of Science ®Google Scholar
• Van Der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Resp J. 2012;21(1):101–108.
   PubMedGoogle Scholar
• Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6:17–25.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Segreti A, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2015;12(2):175–181.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J of Pharm. 2015;761:168–173.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. COPD Pulm Pharmacol Ther. 2010;23(4):257–267.
   PubMed Web of Science ®Google Scholar
• Cohen S, Miles MC, Donohue JF, et al. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J of COPD. 2016;11:785–797.
   Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015−15023.
   PubMed Web of Science ®Google Scholar
• Calverley PMA. COPD: what is the unmet need? Br J Pharmacol. 2008;155:487–493.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183–194.
   PubMedGoogle Scholar
• Valipour A, Lavie P, Lothaller H, et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12:367–372.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Benfante A, Bocchino M, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Ora J, et al. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2016;17(7):977–988.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J of COPD. 2012;7:95–99.
   Google Scholar
• Kendall M, Buckingham S, Ferguson S, et al. Exploring the concept of need in people with very severe chronic obstructive pulmonary disease: a qualitative study. BMJ Support Palliat Care. 2015. doi:10.1136/bmjspcare-2015-000904.
   Google Scholar
• Data from: U.S. Food and Drug Administration, label files, prescribing information. [cited 2016 Jun 1]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.
   Google Scholar
• Data from: HIGHLIGHTS OF PRESCRIBING INFORMATION of Bevespi Aerosphere™; cited Apr 2016 3239006 5/16.
   Google Scholar
• Data from: UK Medicines Information, [cited 2016 Jun 1]. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5371.
   Google Scholar
• Newman SP. Principles of metered-dose inhaler design. Resp Care. 2005;50(9):1177−1190.
   PubMedGoogle Scholar
• Rogueda P. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Exp Opin Drug Delivery. 2005;2(4):625−638.
   PubMedGoogle Scholar
• Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transitionValve performance. J Allergy Clin Immunol. 1999;104(6):s230−s235.
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Vehring R, Dwivedi SK. A new co-Suspension MDI platform: scientific foundations of mono, dual and triple combination products. Poster presented at the Respiratory Drug Delivery (RDD) meeting; 2011; Berlin (Germany). 1. 101–112
   Google Scholar
• Vidya J, Noga B, Lechuga-Ballesteros D, et al. Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform. Poster presented at the Annual Meeting of the European Respiratory Society. Vienna (Austria). Eur Resp J. 2012;40(Suppl 56):P2150.
   Google Scholar
• Vehring R, Hartman M, Schultz R et al. Glycopyrrolate and formoterol fumarate monotherapy and combination metered dose inhalers with high dose uniformity and stable aerosol properties. Poster presented at the Annual Meeting of the American Thoracic Society; 2010 14–19; New Orleans (LA).
   Google Scholar
• Rennard S, Fogarty C, Reisner C, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:118.
   PubMed Web of Science ®Google Scholar
• Cummings RH, Schultz R, Speck JH et al. Performance advantages of pearl cosuspension formulation technology for manufacturing of metered-dose inhalers. Poster presented at the Respiratory Drug Delivery (RDD) meeting; 2011 3–6; Berlin (Germany).
   Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160.
   PubMed Web of Science ®Google Scholar
• Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73:741–753.
   PubMed Web of Science ®Google Scholar
• Sechaud R, Renard D, Zhang-Auberson L, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50:118–128.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• Reisner C, Ferguson GT, St. Rose E, et al. Pearl Therapeutics’ combination lama/laba Mdi (gff-Mdi, Pt003) formulation of formoterol fumarate and glycopyrrolate provides similar systemic exposure to the individual mdi formulations administered alone in patients with COPD following 1-week dosing. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2012;185:A2926.
   Google Scholar
• Quinn D, Seale JP, Reisner C, et al. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respir Med. 2014;108(9):1327–1335.
   PubMed Web of Science ®Google Scholar
• Fabbri L, Rodriguez-Roisin R, Orevillo C, et al. Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators. Poster presented at the Annual Meeting of the European Respiratory Society. Barcelona (Spain). Eur Resp J. 2013;42(Suppl 57):P759.
   Google Scholar
• Reisner C, Orevillo CJ, Fernandez C, et al. Pearl therapuetics’ combination lama/laba (gff mdi, Pt003) provides comparable safety as measured by 24-hour holter monitoring to its components (gp mdi, Pt001 and ff Mdi, Pt005) and Foradil® Aerolizer®. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;187:A1485.
   Web of Science ®Google Scholar
• Martinez FJ, Fabbri LM, Rennard SI, et al. Cardiovascular safety profile of a novel lama/laba co-suspension technology fixed-Dose combination of glycopyrrolate/formoterol delivered by metered dose inhaler in patients with COPD: 24-hour holter monitoring study. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6783.
   Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383–390.
   PubMed Web of Science ®Google Scholar
• Reisner C, Fernandez C, St. Rose E, et al. Characterization of the dose response of pearl therapeutics’ lama mdi (gp mdi, Pt001) from 36 micrograms to 600 nanograms bid; results from an integrated analysis of phase IIb studies in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;187:A4274.
   Web of Science ®Google Scholar
• Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol mdi (gff-mdi) provides superior bronchodilation compared to its components administered alone, tiotropium dpi, and formoterol dpi in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Denver (CO, USA). Am J Respir Crit Care Med. 2011;183:A6435.
   Web of Science ®Google Scholar
• Reisner C, Rennard S, Fogarty C, et al. Pearl therapeutics’ combination lama/laba mdi (gff-mdi, Pt003) provides a significant benefit on home peak expiratory flow rate (pefr) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva® Handihaler®, and Foradil® Aerolizer® in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2012;185:A2259.
   Google Scholar
• Reisner C, Gotfried M, Denenberg MB, et al. Low doses of Pearl therapeutics’ lama/laba Combination mdi (gff mdi, Pt003) provide superior bronchodilation compared to components and to open-label spiriva handihaler in A Randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;87:A2434.
   Google Scholar
• Reisner C, Orevillo C, Fernandez C, et al. Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development. Poster presented at the annual meeting of the European Respiratory Society. Barcelona (Spain). Eur Resp J. 2013;42(Suppl 57):P4153.
   Google Scholar
• Rabe K, Martinez F, Rodriguez-Roisin R, et al. PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. Poster presented at the annual meeting of the European Respiratory Society. Amsterdam (Nederland). Eur Respir J. 2015;46:PA4363.
   Google Scholar
• Martinez FJ, Rabe KF, Rodriguez-Roisin R, et al. Pooled analyses from pinnacle-1 and −2: the novel lama/laba co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by mdi shows improvement versus monocomponents in patients with COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6782.
   Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Rodriguez-Roisin R, et al. Beneficial effect of the novel lama/laba co-suspension technology of glycopyrrolate/formoterol fixed-dose combination delivered by mdi in gold A and B COPD patients: pooled analyses from Pinnacle-1 and −2. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6785.
   Web of Science ®Google Scholar
• Arora S, Delacruz L, Feldman G, et al. 24-hour lung function following the novel lama/laba co-suspension technology of glycopyrrolate/formoterol fixed-dose combination mdi, in patients with moderate-to-very-severe COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6792.
   Web of Science ®Google Scholar
• Martinez FJ, Fabbri LM, Ferguson GT, et al. The novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI significantly improves health status in symptomatic patients with COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6784.
   Web of Science ®Google Scholar
• Hanania NA, Tashkin DP, Kerwin E, et al. Safety and efficacy of a novel lama/laba co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by mdi: results of a one-year extension study in patients with COPD (pinnacle-3). Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6791.
   Web of Science ®Google Scholar
• Reisner C, Gottschlich G, Fakih F, et al. 24-hour lung function profile of novel co-suspension technology glycopyrrolate/formoterol metered dose inhaler versus placebo and Spiriva® Respimat®, in patients with moderate-to-very-severe chronic obstructive pulmonary disease. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6823.
   Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Pooled analyses from Pinnacle-1 and −2: safety profile of the novel lama/laba co-suspension technology fixed-dose combination (glycopyrrolate/formoterol) delivered by mdi, in patients with Chronic Obstructive Pulmonary Disease (COPD). Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6790.
   Web of Science ®Google Scholar
• Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178–184.
   PubMed Web of Science ®Google Scholar